Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study
Articolo
Data di Pubblicazione:
2021
Citazione:
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study / M. Pagnesi, R.M. Inciardi, C.M. Lombardi, P. Agostoni, P. Ameri, L. Barbieri, A. Bellasi, R. Camporotondo, C. Canale, V. Carubelli, S. Carugo, F. Catagnano, L.A.D. Vecchia, G.B. Danzi, M. Di Pasquale, M. Gaudenzi, S. Giovinazzo, M. Gnecchi, M. Guazzi, A. Iorio, M.T. La Rovere, S. Leonardi, G. Maccagni, M. Mapelli, D. Margonato, M. Merlo, L. Monzo, A. Mortara, V. Nuzzi, M. Piepoli, I. Porto, A. Pozzi, F. Sarullo, G. Sinagra, C. Tedino, D. Tomasoni, M. Volterrani, G. Zaccone, M. Senni, M. Metra. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 108:(2021 Jul), pp. 270-273. [10.1016/j.ijid.2021.05.056]
Abstract:
Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). Our aim was to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality.
Methods: We performed a sub-analysis of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between March 1st, 2020, and April 9th, 2020. The primary endpoint was in-hospital mortality.
Results: A total of 706 COVID-19 patients were included (n = 349 treated with glucocorticoids, n = 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44, 95% CI 0.26-0.72, p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effect of glucocorticoids was mainly observed in patients with lower PaO2/FiO2 ratio (<300), lower oxygen saturation (<90%), and higher CRP (>100 mg/L).
Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 was more evident among patients of worse respiratory parameters and higher systemic inflammation.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
COVID-19; SARS-CoV-2; corticosteroid; glucocorticoid; steroid
Elenco autori:
M. Pagnesi, R.M. Inciardi, C.M. Lombardi, P. Agostoni, P. Ameri, L. Barbieri, A. Bellasi, R. Camporotondo, C. Canale, V. Carubelli, S. Carugo, F. Catagnano, L.A.D. Vecchia, G.B. Danzi, M. Di Pasquale, M. Gaudenzi, S. Giovinazzo, M. Gnecchi, M. Guazzi, A. Iorio, M.T. La Rovere, S. Leonardi, G. Maccagni, M. Mapelli, D. Margonato, M. Merlo, L. Monzo, A. Mortara, V. Nuzzi, M. Piepoli, I. Porto, A. Pozzi, F. Sarullo, G. Sinagra, C. Tedino, D. Tomasoni, M. Volterrani, G. Zaccone, M. Senni, M. Metra
Link alla scheda completa: